BCDA
BioCardia, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.17
+5.41%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.12
From 52W high−25.00%
Volume169789.00
Market cap$17.71M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$1.12
From 52W high
−25.00%
Volume
169789.00
Market cap
$17.71M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.0x
P/E (TTM)
—
RSI (14)
55.4
MomentumView details →
1D Return
+5.41%
YTD Return
−8.40%
SummaryUpdated Jun 1, 2026
BioCardia, Inc. (NASDAQ:BCDA) is a clinical-stage regenerative medicine company founded in 1996 and headquartered in Sunnyvale, California. The company develops cellular and cell-derived therapeutics primarily targeting cardiovascular and pulmonary diseases. BioCardia operates as a biotechnology company focused on advancing multiple therapeutic platforms through clinical trials, with particular emphasis on cell therapy treatments for heart failure and chronic myocardial ischemia. The company has been publicly traded since its IPO in November 1996 and currently maintains a small market capitalization as it progresses through various phases of clinical development.
Similar companies
Latest newsMore news →
BioCardia announced that the FDA confirmed the outcome of its Pre-Submission Meeting on the Helix Transendocardial Delivery Catheter System, supporting a follow-on De Novo pre-submission for approval.26d agoBioCardia, Inc. received a notice from NASDAQ on August 19, 2026, stating that the company no longer complies with the minimum bid price requirement under Rule 5550(a)(2), and has until February 16, 2027, to regain compliance.30d ago